Study supports evidence that Rab disruption may be effective strategy for treating multiple myeloma

Roswell Park Cancer Institute (RPCI) researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow. Source link